VIENNA, Aug 18 (Reuters) - Austrian biotech firm Intercell (ICEL.VI: Quote, Profile, Research, Stock Buzz) reported second-quarter revenue that more than doubled to 9 million euros ($13 million), due to an increase in revenue from collaboration and licensing, it said on Monday. The net loss roughly halved to 4 million euros in the three months to June. The company reiterated it expected positive net income in the full year, despite its acquisition of U.S. biotech group Iomai (IOMI.O: Quote, Profile, Research, Stock Buzz).
